Stock listing
NASDAQ:JBIO Jade Biosciences, Inc. Stock
Home listing (NASDAQ) of Jade Biosciences, Inc.
Follow Jade Biosciences, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:JBIO
$15.31 USD -0.18 (-1.2%)
Close on Nov 20, 2026
- Day range
- $15.00 – $15.53 USDNov 20, 2026
- Volume
- 1.02M sharesNov 20, 2026
- Market cap
- $1.06B USDAt the close on Nov 20, 2026 · price × 69.19M shares outstanding
- 52-week range
- $11.02 – $28.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $14.75M USDMedian day 829,500 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:JBIO · Home | $15.31 USD | -0.18 (-1.2%) | 1,021,412 | $15.00 | $15.53 | $15.00 | $15.49 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:JBIO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $15.31 | -0.18 | -1.2% | $15.00 | $15.53 | $15.00 | 1,021,412 | |
| $15.49 | +0.09 | +0.6% | $15.41 | $16.20 | $15.35 | 792,236 | |
| $15.40 | +0.065 | +0.4% | $15.34 | $16.31 | $14.60 | 2,078,547 | |
| $15.34 | -0.805 | -5.0% | $15.85 | $16.08 | $14.95 | 1,130,996 | |
| $16.14 | +0.27 | +1.7% | $16.23 | $16.34 | $15.58 | 593,498 | |
| $15.87 | -0.67 | -4.1% | $16.44 | $16.64 | $15.60 | 880,375 | |
| $16.54 | +0.14 | +0.9% | $16.40 | $17.16 | $15.99 | 678,937 | |
| $16.40 | +0.80 | +5.1% | $15.37 | $16.56 | $15.26 | 895,166 | |
| $15.60 | +0.53 | +3.5% | $15.26 | $16.14 | $14.78 | 739,448 | |
| $15.07 | +0.97 | +6.9% | $14.16 | $15.10 | $13.65 | 595,377 | |
| $14.10 | -0.94 | -6.2% | $15.02 | $15.03 | $14.06 | 1,286,828 | |
| $15.04 | +0.47 | +3.2% | $15.01 | $15.19 | $14.45 | 1,136,185 | |
| $14.57 | +0.64 | +4.6% | $14.11 | $14.85 | $14.08 | 1,448,882 | |
| $13.93 | -0.13 | -0.9% | $14.44 | $14.44 | $13.55 | 718,189 | |
| $14.06 | -0.18 | -1.3% | $14.13 | $14.35 | $13.83 | 682,307 | |
| $14.24 | -0.35 | -2.4% | $14.71 | $14.93 | $14.16 | 896,089 | |
| $14.59 | -0.15 | -1.0% | $14.57 | $14.90 | $14.13 | 671,339 | |
| $14.74 | +0.24 | +1.7% | $14.52 | $15.07 | $14.36 | 652,895 | |
| $14.50 | -0.09 | -0.6% | $14.69 | $15.04 | $14.37 | 477,455 | |
| $14.59 | -0.32 | -2.1% | $14.89 | $15.00 | $14.54 | 634,374 | |
| $14.91 | -0.22 | -1.5% | $15.04 | $15.44 | $14.36 | 575,900 | |
| $15.13 | +0.27 | +1.8% | $14.84 | $15.43 | $14.72 | 932,700 | |
| $14.86 | +1.03 | +7.4% | $13.93 | $14.96 | $13.73 | 881,300 | |
| $13.83 | +0.36 | +2.7% | $13.86 | $14.10 | $13.54 | 828,500 | |
| $13.47 | -0.29 | -2.1% | $13.78 | $14.10 | $13.03 | 981,000 | |
| $13.76 | +0.32 | +2.4% | $13.54 | $14.18 | $13.45 | 1,038,900 | |
| $13.44 | +0.02 | +0.1% | $13.22 | $13.66 | $12.85 | 1,172,700 | |
| $13.42 | -0.58 | -4.1% | $14.00 | $14.24 | $13.35 | 1,329,200 | |
| $14.00 | -0.39 | -2.7% | $14.33 | $14.45 | $13.82 | 1,355,600 | |
| $14.39 | +0.24 | +1.7% | $14.16 | $14.81 | $14.00 | 735,600 | |
| $14.15 | +0.38 | +2.8% | $13.58 | $14.15 | $13.18 | 1,667,200 | |
| $13.77 | +0.36 | +2.7% | $13.19 | $14.14 | $13.08 | 951,300 | |
| $13.41 | -0.66 | -4.7% | $14.20 | $14.34 | $13.15 | 493,900 | |
| $14.07 | -0.05 | -0.4% | $14.21 | $14.71 | $13.79 | 607,100 | |
| $14.12 | +0.35 | +2.5% | $13.86 | $14.17 | $13.31 | 1,109,800 | |
| $13.77 | -0.28 | -2.0% | $13.97 | $14.58 | $13.59 | 1,071,700 | |
| $14.05 | -0.13 | -0.9% | $14.43 | $14.74 | $13.95 | 930,900 | |
| $14.18 | -0.17 | -1.2% | $14.35 | $14.66 | $13.77 | 627,500 | |
| $14.35 | -0.07 | -0.5% | $14.29 | $14.71 | $14.08 | 598,600 | |
| $14.42 | -0.31 | -2.1% | $14.81 | $15.20 | $14.39 | 525,800 | |
| $14.73 | +0.02 | +0.1% | $14.59 | $15.06 | $14.45 | 1,051,300 | |
| $14.71 | -2.05 | -12.2% | $16.64 | $16.64 | $14.58 | 1,464,700 | |
| $16.76 | +0.02 | +0.1% | $16.92 | $17.16 | $16.60 | 643,900 | |
| $16.74 | -0.20 | -1.2% | $17.12 | $17.67 | $16.49 | 528,800 | |
| $16.94 | -0.20 | -1.2% | $17.15 | $17.35 | $16.79 | 2,942,200 | |
| $17.14 | +0.49 | +2.9% | $17.03 | $17.74 | $16.94 | 815,700 | |
| $16.65 | -0.73 | -4.2% | $17.52 | $17.61 | $16.16 | 1,730,500 | |
| $17.38 | -0.80 | -4.4% | $18.16 | $18.16 | $17.02 | 849,800 | |
| $18.18 | +0.29 | +1.6% | $18.06 | $18.83 | $17.88 | 829,500 | |
| $17.89 | -1.25 | -6.5% | $19.38 | $20.10 | $17.53 | 1,249,200 | |
| $19.14 | +0.08 | +0.4% | $18.82 | $19.33 | $18.59 | 1,224,900 | |
| $19.06 | -0.39 | -2.0% | $19.43 | $19.98 | $18.79 | 1,507,500 | |
| $19.45 | -0.45 | -2.3% | $19.67 | $20.15 | $19.00 | 825,600 | |
| $19.90 | +0.05 | +0.3% | $19.86 | $20.35 | $19.70 | 605,000 | |
| $19.85 | -1.55 | -7.2% | $21.00 | $21.27 | $19.76 | 1,381,800 | |
| $21.40 | +0.38 | +1.8% | $21.17 | $22.00 | $20.48 | 506,200 | |
| $21.02 | -0.34 | -1.6% | $21.32 | $21.62 | $20.73 | 516,600 | |
| $21.36 | +0.52 | +2.5% | $20.65 | $21.45 | $20.35 | 837,000 | |
| $20.84 | -0.45 | -2.1% | $21.07 | $21.40 | $20.81 | 357,900 | |
| $21.29 | -0.04 | -0.2% | $21.26 | $21.85 | $21.13 | 342,600 | |
| $21.33 | -0.51 | -2.3% | $22.40 | $22.40 | $21.20 | 355,900 | |
| $21.84 | +0.51 | +2.4% | $21.74 | $22.16 | $21.33 | 603,500 | |
| $21.33 | -0.01 | 0.0% | $21.27 | $21.78 | $20.40 | 595,700 | |
| $21.34 | +0.11 | +0.5% | $21.45 | $22.12 | $21.13 | 571,800 | |
| $21.23 | -1.32 | -5.9% | $23.82 | $23.82 | $20.70 | 936,600 |
- Ticker
- NASDAQ:JBIO
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 13, 2026
Jade Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 49 slides
Latest news
Jade Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nov 13, 2026
Closed $16.14 (+1.7%) on Nov 13, 2026
Jade Biosciences to Participate in Upcoming Conferences
Nov 3, 2026
Closed $14.57 (+4.6%) on Nov 3, 2026
Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026
Oct 21, 2026
Closed $15.13 (+1.8%) on Oct 21, 2026
Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
Sep 30, 2026
Closed $14.05 (-0.9%) on Sep 30, 2026
Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Aug 10, 2026
Closed $21.73 (-1.0%) on Aug 10, 2026
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
Jun 26, 2026
Closed $22.00 (+0.9%) on Jun 26, 2026
Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Jun 5, 2026
Closed $14.98 (-11.6%) on Jun 8, 2026
Jade Biosciences Announces Pricing of Public Offering of Common Stock
Jun 3, 2026
Closed $17.74 (+0.9%) on Jun 4, 2026
Jade Biosciences Announces Proposed Underwritten Public Offering
Jun 3, 2026
Closed $17.74 (+0.9%) on Jun 4, 2026
Jade Biosciences, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 20 in the last 12 months · 69 in all · newest Nov 13, 2026 · oldest 2021
- Decks
- 26 decks · latest November 2026
Where Jade Biosciences, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:JBIO · Home listing · This page | NASDAQ | United States | USD |
| BOATS:JBIO | BOATS | United States | USD |
Valuation
Price/book 2.3× against a median of 3.8×: 3rd lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $583.6M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.3×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.14
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Jade Biosciences, Inc. · NASDAQ:JBIO | US$1.06B | US$583.6M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | 1.14 |
| Shenzhen Chipscreen Biosciences Co. Ltd. Class A · SSE:688321 | US$1.10B | US$1.10B | 102× | 6.8× | n/a | 2.9× | 6.6% | 0.5× | n/a |
| Pharma Mar SA · BME:PHM | US$1.10B | US$978.5M | 14.6× | 3.8× | 16.6× | 4.2× | 28.8% | 0.3× | n/a |
| Alpha Tau Medical Ltd · NASDAQ:DRTS | US$1.09B | US$1.00B | n/a | n/a | n/a | 55.3× | n/a | 0.8× | 1.89 |
| Kardigan, Inc. · NASDAQ:KARD | US$1.08B | US$621.1M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | n/a |
| PYC Therapeutics Limited · ASX:PYC | US$1.07B | US$775.8M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | n/a |
| MedinCell SA · EURONEXT:MEDCL | US$1.05B | US$1.02B | n/a | 38.4× | n/a | 313× | −128.9% | 18.7× | n/a |
| Nektar Therapeutics · NASDAQ:NKTR | US$1.03B | US$492.8M | n/a | 9.4× | n/a | 1.2× | −339.7% | 0.1× | 1.28 |
| Mabwell (Shanghai) Bioscience Co., Ltd. Class A · SSE:688062 | US$1.02B | US$984.8M | n/a | 9.2× | n/a | 9.5× | −146.4% | 2.9× | n/a |
| SpyGlass Pharma, Inc. · NASDAQ:SGP | US$1.02B | US$809.5M | n/a | n/a | n/a | 4.8× | n/a | 0.0× | 1.01 |
| Alto Neuroscience, Inc. · NYSE:ANRO | US$1.02B | US$711.7M | n/a | n/a | n/a | 3.4× | n/a | 0.1× | 1.65 |
| Median of the others | US$1.06B | US$894.0M | 58.5× | 9.2× | 16.6× | 3.8× | −128.9% | 0.2× | 1.47 |
Forecasts
10 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 49.38 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.93 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Lawrence Klein | Chief Executive Officer, Oruka Therapeutics |
| Tom Frohlich | Chief Executive Officer |
| Brad Dahms | Chief Financial Officer |
| Andrew King | President, Research & Development |
| Elizabeth Balta | Chief Legal Officer & Corporate Secretary |
| Amy Sullivan | Senior Vice President, Development Operations |
| Jonathan Quick | Senior Vice President, Finance |
| Lori Stewart | Senior Vice President, People |
| Sandy Lewis | Senior Vice President, Biometrics and Clinical Strategy |
| Valerie Fauvelle | Senior Vice President, Regulatory & Quality |
| Chris Cain | Director of Research, Fairmount |
| Edward R. Conner | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Mark Eisner | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 13, 2026 · Before open | +1.7% |
| Q2 2026 | Aug 10, 2026 · Before open | −1.1% |
| Q1 2026 | May 7, 2026 · After close | +6.6% |
| Q3 2025 | Nov 12, 2025 · After close | −3.2% |
| Q2 2025 | Aug 13, 2025 · After close | −7.6% |
| Q1 2025 | May 14, 2025 · After close | −2.0% |
| Q4 2024 | Mar 26, 2025 | |
| Q3 2024 | Nov 11, 2024 | |
| Q2 2024 | Aug 12, 2024 | |
| Q1 2024 | May 13, 2024 |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Mar 25, 2024 | |
| Q3 2023 | Nov 13, 2023 | |
| Q2 2023 | Aug 14, 2023 | |
| Q1 2023 | May 16, 2023 | |
| Q4 2022 | Mar 29, 2023 | |
| Q3 2022 | Nov 14, 2022 | |
| Q2 2022 | Aug 17, 2022 | |
| Q1 2022 | May 16, 2022 | |
| Q4 2021 | Mar 30, 2022 | |
| Quarter to Sep 30, 2021 | Nov 15, 2021 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 49 slides | November 2026 |
| Investor Presentation (October 2026) | Investor deck | 49 slides | October 2026 |
| Corporate Update (September 2026) | Corporate update | 18 slides | Sep 30, 2026 |
| Investor Presentation (September 2026) | Investor deck | 48 slides | September 2026 |
| Investor Presentation (August 2026) | Investor deck | 45 slides | August 2026 |
| Investor Presentation (July 2026) | Investor deck | 38 slides | July 2026 |
| Investor Presentation (June 2026) | Investor deck | 39 slides | June 2026 |
| Technical Presentation (June 2026) | Technical | 22 slides | Jun 1, 2026 |
| Investor Presentation (May 2026) | Investor deck | 35 slides | May 2026 |
| Investor Presentation (March 2026) | Investor deck | 35 slides | March 2026 |
All 26 decks
Financings
| Raise | Date |
|---|---|
| Private placement of shares of common stock Announced: about US$45M · US$14 a share Buyers: BB Biotech (3,214,286 shares of common stock for approximately $45 million) Use of proceeds: Research and development, general corporate expenses, and working capital | Dec 15, 2025 |
| Private placement of common stock and pre-funded warrants Announced: about US$135M · US$9.14 a share · Jefferies +3 Dealers: Jefferies, TD Cowen, Stifel, Wedbush & Co. Buyers: Janus Henderson Investors; Fairmount; RA Capital Management; Marshall Wace; Aberdeen Investments; Great Point Partners, LLC; Venrock Healthcare Capital Partners; Samsara BioCapital; Avidity Partners Use of proceeds: To fund research and development, general corporate expenses, and working capital needs | Oct 7, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Aerovate Therapeutics, Inc. Priced at US$14.00 a share on Jun 29, 2021.
- Price
- US$14.00 a share
- Shares offered
- 8,682,142 shares of common stock
- Offering size
- US$121.5 million
- Underwriters' option
- Up to 1,302,321 more shares
- Listing
- AVTE on the Nasdaq Global Market
- Underwriters
- Jefferies, Cowen, Evercore ISI, Wedbush PacGrow · In the order on the cover
- Shares delivered
- On or about Jul 2, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 6, 2021 |
| Filed publicly | Jun 9, 2021 |
| Amended 3 times | Newest Jun 25, 2021 |
| Shares registered with an exchange | Jun 25, 2021 |
| Declared effective by the SEC | Jun 29, 2021 |
| Final prospectus, with the price | Jun 30, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jun 30, 2021 |
| EFFECT · Notice that a registration is effective | Jun 29, 2021 |
| S-1MEF · Registration of more shares for the same offering | Jun 29, 2021 |
| CERT · Exchange's certificate of listing | Jun 29, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Jun 25, 2021 |
| CORRESP · Letter to the SEC | Jun 25, 2021 |
| CORRESP · Letter to the SEC | Jun 25, 2021 |
| S-1/A · Registration statement, amended | Jun 25, 2021 |
| CORRESP · Letter to the SEC | Jun 24, 2021 |
| S-1/A · Registration statement, amended | Jun 24, 2021 |
All 16 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Jun 21, 2021 |
| S-1/A · Registration statement, amended | Jun 17, 2021 |
| CORRESP · Letter to the SEC | Jun 9, 2021 |
| S-1 · Registration statement | Jun 9, 2021 |
| UPLOAD · Letter from the SEC | Jun 2, 2021 |
| DRS · Draft registration statement | May 6, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Jun 30, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | |||||
| Cost of revenue | 26.0K | 282.0K | 96.0K | 68.0K | 15.0K | 1.00K |
| Gross profit | -26.0K | -282.0K | -96.0K | -68.0K | -15.0K | -1.00K |
| Research and development | 93.1M | 53.2M | 64.2M | 38.6M | 15.0M | 7.94M |
| Selling, general and administrative | 20.2M | 8.61K | ||||
| Operating income | -113.5M | -74.6M | -81.4M | -53.2M | -23.0M | -8.89M |
| Depreciation and amortization | 26.0K | 282.0K | 96.0K | 68.0K | 15.0K | 1.00K |
| EBITDA | -113.5M | -74.3M | -81.3M | -53.2M | -23.0M | -8.89M |
| Interest expense | 75.0K | |||||
| Income before tax | -127.4M | -69.6M | -75.5M | -51.5M | -23.0M | -9.61M |
| Income tax | 58.0K | 55.0K | 56.0K | 25.0K | 3.00K | |
| Net income | -127.4M | -69.6M | -75.5M | -51.5M | -23.0M | -9.61M |
| Earnings per share, basic | -3.19 | -2.44 | -2.87 | -2.10 | -1.87 | -40.31 |
| Earnings per share, diluted | -3.19 | -2.44 | -2.87 | -2.10 | -1.87 | -40.31 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 88.4M | 69.4M | 23.5M | 22.4M | 54.2M | 4.57M |
| Short-term investments | 247.7M | 0 | 98.9M | 106.8M | 113.2M | |
| Current assets | 348.8M | 69.7M | 124.2M | 131.5M | 174.3M | 4.68M |
| Property, plant and equipment | 170.0K | 0 | 288.0K | 242.0K | 186.0K | 39.0K |
| Total assets | 349.8M | 72.8M | 127.4M | 135.3M | 175.4M | 4.71M |
| Accounts payable | 2.15M | 1.29M | 2.40M | 2.58M | 1.21M | 618.0K |
| Current liabilities | 16.5M | 12.0M | 17.6M | 7.78M | 2.55M | 1.77M |
| Long-term debt | 107.6M | |||||
| Total debt | 724.0K | 417.0K | 675.0K | 1.09M | 574.0K | |
| Total liabilities | 17.3M | 119.6M | 18.0M | 8.56M | 2.94M | 1.77M |
| Shareholders' equity | 332.5M | -46.8M | 109.5M | 126.7M | 172.4M | -13.3M |
| Shares outstanding | 49.3M | 3.67M | 27.8M | 24.7M | 24.4M | 243.1K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | -94.7M | -71.2M | -56.8M | -39.1M | -27.4M | -7.86M |
| Capital spending | -196.0K | 0 | -142.0K | -195.0K | -181.0K | 0 |
| Free cash flow | -94.9M | -71.2M | -56.9M | -39.3M | -27.6M | -7.86M |
| Cash from investing | -247.0M | 56.0M | 11.9M | 6.93M | -113.4M | |
| Cash from financing | 360.8M | 25.4M | 46.0M | 396.0K | 190.5M | 8.92M |
| Change in cash | 19.1M | 10.3M | 1.09M | -31.8M | 49.6M | 1.06M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 28, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Sep 30, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 10, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 8, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 1, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 26, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 26, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2026 | Meeting outcome | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 9, 2026 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Jun 5, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jun 4, 2026 | Current report | SEC |
| 424B5 · Prospectus | Jun 4, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Jun 3, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 1, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | May 18, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | May 18, 2026 | Other filings | SEC |
| 424B3 · Prospectus | May 15, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| CORRESP · Letter to the SEC | May 13, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 13, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 13, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 13, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | May 7, 2026 | Offer document | SEC |
| S-3 · Registration statement | May 7, 2026 | Offer document | SEC |
| S-3 · Registration statement | May 7, 2026 | Offer document | SEC |
| 424B3 · Prospectus | May 7, 2026 | Offer document | SEC |
| 424B3 · Prospectus | May 7, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 28, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Apr 22, 2026 | Management or board change | SEC |
| PRE 14A · Preliminary proxy statement | Apr 17, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 2, 2026 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Mar 6, 2026 | Offer document | SEC |
| POS EX | Mar 6, 2026 | Other filings | SEC |
| POS EX | Mar 6, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Mar 6, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Mar 6, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 6, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 6, 2026 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 5, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 30, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 5, 2026 | Results | SEC |
| EFFECT · Notice that a registration is effective | Dec 31, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Dec 30, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Dec 23, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 23, 2025 | Other filings | SEC |
| S-1 · Registration statement | Dec 22, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 22, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Dec 19, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Dec 17, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 15, 2025 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| S-1 · Registration statement | Nov 14, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 17, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 16, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 8, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 8, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 7, 2025 | Material contract | SEC |
| 8-K · Current report | Sep 9, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 8-A12B/A · Registration of shares for listing on an exchange, amended | Aug 13, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 29, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 14, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 14, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 1, 2025 | Material contract | SEC |
| S-8 · Registration statement for employee plans | Jun 30, 2025 | Offer document | SEC |
| 144 · Notice of proposed sale | Jun 25, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 25, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 24, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 20, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 6, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| 144 · Notice of proposed sale | May 6, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | May 6, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | May 5, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 5, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | May 1, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 1, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 1, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 1, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 1, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 1, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 1, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 1, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 1, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 1, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 1, 2025 | Insider trade | SEC |
| 8-K · Current report | May 1, 2025 | Results | SEC |
| 4 · Change in ownership | Apr 30, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 30, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 30, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Apr 29, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Apr 25, 2025 | Quarterly report | SEC |
| 8-K · Current report | Apr 23, 2025 | Current report | SEC |
| 8-K · Current report | Apr 21, 2025 | Meeting outcome | SEC |
| 425 | Apr 9, 2025 | Other filings | SEC |
| 425 | Apr 9, 2025 | Other filings | SEC |
| 8-K · Current report | Apr 9, 2025 | Current report | SEC |
| 425 | Apr 9, 2025 | Other filings | SEC |
| 8-K · Current report | Apr 9, 2025 | Current report | SEC |
| 425 | Apr 7, 2025 | Other filings | SEC |
| 425 | Apr 7, 2025 | Other filings | SEC |
| 8-K · Current report | Apr 7, 2025 | Current report | SEC |
| SEC STAFF LETTER | Mar 27, 2025 | Other filings | SEC |
| 10-K · Annual report | Mar 27, 2025 | Annual report | SEC |
| 425 | Mar 26, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Mar 26, 2025 | Other filings | SEC |
| ARS · Annual report to shareholders | Mar 25, 2025 | Annual report | SEC |
| 424B3 · Prospectus | Mar 25, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Mar 24, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 24, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 24, 2025 | Other filings | SEC |
| S-4/A · Registration statement, amended | Mar 24, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Mar 21, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 14, 2025 | Other filings | SEC |
| S-4/A · Registration statement, amended | Mar 14, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Mar 11, 2025 | Other filings | SEC |
| 425 | Mar 3, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 24, 2025 | Other filings | SEC |
| S-4/A · Registration statement, amended | Feb 24, 2025 | Offer document | SEC |
| SEC STAFF LETTER | Feb 19, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 18, 2025 | Other filings | SEC |
| 425 | Feb 10, 2025 | Other filings | SEC |
| 425 | Feb 4, 2025 | Other filings | SEC |
| 425 | Jan 24, 2025 | Other filings | SEC |
| S-4/A · Registration statement, amended | Jan 22, 2025 | Offer document | SEC |
| 425 | Jan 13, 2025 | Other filings | SEC |
| S-4 · Registration statement | Dec 3, 2024 | Offer document | SEC |
| RW · Request to withdraw a registration | Nov 25, 2024 | Other filings | SEC |
| 425 | Nov 18, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 425 | Oct 31, 2024 | Other filings | SEC |
| 425 | Oct 31, 2024 | Other filings | SEC |
| 425 | Oct 31, 2024 | Other filings | SEC |
| 425 | Oct 31, 2024 | Other filings | SEC |
| 425 | Oct 31, 2024 | Other filings | SEC |
| 8-K · Current report | Oct 31, 2024 | Material contract | SEC |
| 8-K · Current report | Oct 17, 2024 | Current report | SEC |
| 8-K · Current report | Oct 10, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 2, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 8, 2024 | Current report | SEC |
| 8-K/A · Current report, amended | Jul 1, 2024 | Current report | SEC |
| 8-K · Current report | Jun 28, 2024 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Jun 20, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 20, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 17, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 14, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 13, 2024 | Other filings | SEC |
| S-3 · Registration statement | Jun 10, 2024 | Offer document | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
This page holds 200 of 515 filings. Open Filings
Cap table
Built by 6ix from Jade Biosciences, Inc.’s releases · as of Nov 6, 2026
- Common shares
- 69,189,448
- Fully diluted
- 69,189,448
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 69,189,448 | Nov 6, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 6, 2026 | 69,189,448 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Rajeev M Shah Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past) | Director · Jun 29, 2021 – Jun 17, 2024 · Past |
| Habib Joseph Dable Other companies: Tyra Biosciences, Inc. (Director · Since at least Apr 16, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Relay Therapeutics, Inc. (Director · Since at least Nov 4, 2025); Day One Biopharmaceuticals Inc (Director · Since at least Jan 17, 2024); PepGen Inc. (Director · Since at least Sep 20, 2022); Blueprint Medicines Corp (Director · Since at least Jun 23, 2022); Albireo Pharma Inc (Director · Aug 8, 2022 – Mar 2, 2023 · Past); Acceleron Pharma Inc (CEO and President, Director · Jan 4, 2021 – Nov 19, 2021 · Past) | Director · Jul 10, 2023 – Jun 5, 2024 · Past |
| Mark Iwicki Other companies: Inhibikase Therapeutics, Inc. (Chief Executive Officer - Inhibikase · Since at least Feb 14, 2025); Q32 Bio Inc. (Director · Since at least Mar 25, 2024); Third Harmonic Bio Inc. (Director · Since at least Sep 14, 2022); Akero Therapeutics Inc (Director · Since at least Jun 19, 2019); Kala Bio, Inc. (Director · Since at least Jul 19, 2017); Pulmatrix, Inc. (Director · Mar 20, 2017 – Jan 28, 2021 · Past); Aimmune Therapeutics Inc (Director · May 25, 2016 – Oct 10, 2020 · Past) | Director · Apr 2, 2021 – Jun 5, 2024 · Past |
| Edward R. Conner Other companies: Ardelyx, Inc. (Chief Medical Officer · Since at least Aug 1, 2025); Third Harmonic Bio Inc. (Chief Medical Officer · Sep 14, 2022 – Jan 15, 2025 · Past); Enliven Therapeutics, Inc. (Director · Apr 22, 2020 – Jun 2, 2022 · Past); Audentes Therapeutics Inc (SVP, Chief Medical Officer · Jul 15, 2019 – Jan 15, 2020 · Past); Sangamo Therapeutics, Inc. (Sr. VP & Chief Medical Officer · Nov 30, 2016 – Jan 24, 2019 · Past) | Chief Medical Officer · Since at least Apr 23, 2026 |
| Eric Dobmeier Other companies: Janux Therapeutics, Inc. (Director · Since at least Jul 19, 2024); Structure Therapeutics, Inc. (Director · Since at least Feb 2, 2023); Aduro Biotech Inc (President, CEO, Director · Oct 5, 2020 – Aug 11, 2023 · Past); Atara Biotherapeutics, Inc. (Director · Jun 27, 2019 – Nov 10, 2023 · Past); Adaptive Biotechnologies Corporation (Director · Jun 26, 2019 – Feb 14, 2021 · Past) | Director · Since at least Apr 28, 2025 |
| Allison Dorval Other companies: Verve Therapeutics Inc (Chief Financial Officer · Since at least Nov 29, 2021); Puma Biotechnology Inc (Director · Since at least Jul 15, 2021); Voyager Therapeutics, Inc. (Chief Financial Officer · Jun 8, 2018 – Mar 19, 2021 · Past); Insulet Corporation (Chief Financial Officer · Nov 6, 2014 – Apr 1, 2015 · Past) | Director · Jul 15, 2021 – Jun 5, 2024 · Past |
| Erin Lavelle Other companies: Avalyn Pharma Inc. (Director · Since at least Apr 29, 2026); Neurogene Inc. (Director · May 12, 2022 – Jun 8, 2023 · Past); Climb Bio, Inc. (COO & CFO · Aug 9, 2021 – Oct 31, 2022 · Past); Alder BioPharmaceuticals Inc (Chief Operating Officer · Apr 16, 2018 – Oct 22, 2019 · Past) | Director · Since at least Apr 28, 2025 |
| Joshua Resnick Other companies: Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Cidara Therapeutics Inc (Director · Since at least Jan 3, 2025); PepGen Inc. (Director · Since at least Jun 20, 2024); Vor Biopharma Inc. (Director · May 23, 2024 – May 22, 2025 · Past) | Director · Jun 5, 2024 – Jun 5, 2024 · Past |
| Chris Cain Other companies: Damora Therapeutics, Inc. (Board Director · Since at least Nov 10, 2025); Viridian Therapeutics, Inc. (Director · Since at least Mar 10, 2025); Cogent Biosciences, Inc. (Director · Since at least Jul 6, 2020) | Director · Since at least Apr 28, 2025 |
| Bradford D Dahms Other companies: Theseus Pharmaceuticals Inc (President and CFO · Oct 6, 2021 – Feb 14, 2024 · Past); Cartesian Therapeutics, Inc. (Chief Financial Officer · Sep 3, 2019 – Jan 4, 2021 · Past) | Chief Financial Officer · Since at least Jul 14, 2025 |
All 30 people
| Person | Seat |
|---|---|
| David Grayzel Other companies: Q32 Bio Inc. (Director · Since at least Mar 25, 2024); Surface Oncology Inc (Director · Apr 18, 2018 – Sep 8, 2023 · Past) | Director · Feb 1, 2021 – Jun 5, 2024 · Past |
| Maha Katabi Other companies: RayzeBio, Inc. (Director · Sep 14, 2023 – Feb 26, 2024 · Past); Vera Therapeutics, Inc. (Director · May 13, 2021 – May 14, 2025 · Past) | Director · Feb 1, 2021 – Jun 5, 2024 · Past |
| Mark Eisner Other companies: Zura Bio Limited (Director · Since at least Feb 21, 2026); Vir Biotechnology, Inc. (EVP and Chief Medical Officer · Since at least Jun 3, 2024) | Director · Since at least Jun 25, 2026 |
| Andrew King Other companies: Aduro Biotech Inc (Chief Scientific Officer · Oct 5, 2020 – Aug 11, 2023 · Past) | President, Research & Development · Since at least Apr 28, 2025 |
| Chris Cain Other companies: Cogent Biosciences, Inc. (Member of the Compensation Committee, Chair of the Science & Technology Committee · Since at least Nov 4, 2026) | Director of Research, Fairmount · Since at least Nov 4, 2026 |
| Elizabeth Bekiroglu Other companies: Icosavax Inc (General Counsel & Corp. Sec. · Sep 21, 2021 – Feb 15, 2023 · Past) | See Remarks · Since at least Apr 28, 2025 |
| Tom Frohlich Other companies: Aduro Biotech Inc (Chief Operating Officer · Oct 5, 2020 – Aug 11, 2023 · Past) | Chief Executive Officer, Director · Since at least Apr 28, 2025 |
| Amy Sullivan | Senior Vice President, Development Operations · Since at least Nov 5, 2026 |
| Brad Dahms | Chief Financial Officer · Since at least Jul 1, 2025 |
| Elizabeth Balta | Chief Legal Officer & Corporate Secretary · Since at least Nov 5, 2026 |
| Hetal Kocinsky | Chief Medical Officer · Apr 28, 2025 – Apr 28, 2025 · Past |
| Hunter Gillies | CHIEF MEDICAL OFFICER · Apr 2, 2021 – Jun 13, 2024 · Past |
| Jonathan Quick | Senior Vice President, Finance · Since at least Apr 28, 2025 |
| Lawrence Klein | Chief Executive Officer, Oruka Therapeutics · Since at least Nov 5, 2026 |
| Lori Stewart | Senior Vice President, People · Since at least Nov 5, 2026 |
| Marinus Verwijs | CHIEF TECHNICAL OFFICER · Mar 21, 2022 – Jun 14, 2024 · Past |
| Ralph Niven | CHIEF SCIENTIFIC OFFICER · Apr 2, 2021 – Feb 5, 2024 · Past |
| Sandy Lewis | Senior Vice President, Biometrics and Clinical Strategy · Since at least Nov 4, 2026 |
| Tom Frohlich | Chief Executive Officer · Since at least Aug 10, 2026 |
| Valerie Fauvelle | Senior Vice President, Regulatory & Quality · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Jade Biosciences, Inc.